Company profile
AYTU BIOPHARMA, INC
NASDAQ:AYTUBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CAPROMAB PENDETIDE | approved | — | 0 | — |
| Carbinoxamine maleate | approved | — | 0 | — |
| Rabeprazole sodium | approved | — | 0 | — |
| Zolpidem tartrate | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07169162 | phase4 | withdrawn | 2019-05-01 | 2025-09-05 | Aytu BioPharma, Inc. | ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder |
| NCT05463679 | phase3 | suspended | 2025-01-01 | 2025-06-01 | Aytu BioPharma, Inc. | Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103608 | BLA | Aytu BioScience, Inc. | ||||
Loading… | ||||||
| NDA 022196 | NDA | AYTU BIOSCIENCE INC | ||||
Loading… | ||||||
| NDA 022556 | NDA | AYTU BIOSCIENCE INC | ||||
Loading… | ||||||
| NDA 204736 | NDA | AYTU BIOSCIENCE INC | ||||
Loading… | ||||||